MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) saw a large decline in short interest in May. As of May 29th, there was short interest totaling 457,830 shares, a decline of 49.7% from the May 14th total of 910,289 shares. Based on an average daily trading volume, of 718,711 shares, the short-interest ratio is presently 0.6 days. Approximately 0.9% of the shares of the stock are sold short.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds have recently modified their holdings of the stock. Perkins Capital Management Inc. boosted its position in MDxHealth by 7.1% during the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after purchasing an additional 97,500 shares during the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of MDxHealth during the 3rd quarter valued at about $1,826,000. FreeGulliver LLC grew its stake in shares of MDxHealth by 25.7% in the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after buying an additional 65,000 shares in the last quarter. Renaissance Technologies LLC increased its holdings in MDxHealth by 21.8% in the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after buying an additional 54,600 shares during the last quarter. Finally, Mink Brook Asset Management LLC increased its holdings in MDxHealth by 64.9% in the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after buying an additional 103,686 shares during the last quarter.

MDxHealth Price Performance

NASDAQ:MDXH opened at $0.54 on Friday. The stock has a market cap of $26.84 million, a PE ratio of -0.83 and a beta of 1.36. MDxHealth has a fifty-two week low of $0.51 and a fifty-two week high of $5.33. The stock’s 50-day moving average is $1.49 and its two-hundred day moving average is $2.74.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. On average, equities research analysts anticipate that MDxHealth will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MDXH. BTIG Research decreased their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Lake Street Capital cut their price target on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, May 14th. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. Finally, Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, MDxHealth presently has an average rating of “Moderate Buy” and a consensus target price of $4.63.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.